174 related articles for article (PubMed ID: 21381016)
1. Timing of administration of bevacizumab chemotherapy affects wound healing after chest wall port placement.
Erinjeri JP; Fong AJ; Kemeny NE; Brown KT; Getrajdman GI; Solomon SB
Cancer; 2011 Mar; 117(6):1296-301. PubMed ID: 21381016
[TBL] [Abstract][Full Text] [Related]
2. Wound dehiscence or failure to heal following venous access port placement in patients receiving bevacizumab therapy.
Zawacki WJ; Walker TG; DeVasher E; Halpern EF; Waltman AC; Wicky ST; Ryan DP; Kalva SP
J Vasc Interv Radiol; 2009 May; 20(5):624-7; quiz 571. PubMed ID: 19328717
[TBL] [Abstract][Full Text] [Related]
3. Wound healing and catheter thrombosis after implantable venous access device placement in 266 breast cancers treated with bevacizumab therapy.
Kriegel I; Cottu PH; Fourchotte V; Sanchez S; Fromantin I; Kirov K; Guillaume A; Pelloquin A; Esteve M; Salmon RJ
Anticancer Drugs; 2011 Nov; 22(10):1020-3. PubMed ID: 21970853
[TBL] [Abstract][Full Text] [Related]
4. Incidence of port site complications in relation to timing of bevacizumab infusion.
Yun J; Baek G; Indorf A; Duong A
J Oncol Pharm Pract; 2024 Apr; ():10781552241245037. PubMed ID: 38689544
[TBL] [Abstract][Full Text] [Related]
5. A review on bevacizumab and surgical wound healing: an important warning to all surgeons.
Gordon CR; Rojavin Y; Patel M; Zins JE; Grana G; Kann B; Simons R; Atabek U
Ann Plast Surg; 2009 Jun; 62(6):707-9. PubMed ID: 19461291
[TBL] [Abstract][Full Text] [Related]
6. Impact of bevacizumab chemotherapy on craniotomy wound healing.
Clark AJ; Butowski NA; Chang SM; Prados MD; Clarke J; Polley MY; Sughrue ME; McDermott MW; Parsa AT; Berger MS; Aghi MK
J Neurosurg; 2011 Jun; 114(6):1609-16. PubMed ID: 21142749
[TBL] [Abstract][Full Text] [Related]
7. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab.
Scappaticci FA; Fehrenbacher L; Cartwright T; Hainsworth JD; Heim W; Berlin J; Kabbinavar F; Novotny W; Sarkar S; Hurwitz H
J Surg Oncol; 2005 Sep; 91(3):173-80. PubMed ID: 16118771
[TBL] [Abstract][Full Text] [Related]
8. Indwelling central venous access port insertion during bevacizumab-based therapy.
Grenader T; Goldberg A; Verstandig A; Shavit L
Anticancer Drugs; 2010 Aug; 21(7):704-7. PubMed ID: 20517148
[TBL] [Abstract][Full Text] [Related]
9. Outpatient placement of subcutaneous venous access ports reduces the rate of infection and dehiscence compared with inpatient placement.
Pandey N; Chittams JL; Trerotola SO
J Vasc Interv Radiol; 2013 Jun; 24(6):849-54. PubMed ID: 23582442
[TBL] [Abstract][Full Text] [Related]
10. Trapezius Port Placement in Patients with Breast Cancer: Long-Term Follow-up and Quality-of-Life Assessment.
Çil BE; Öcal O; Eldem FG; Peynircioğlu B; Balkancı F
J Vasc Interv Radiol; 2019 Jan; 30(1):69-73. PubMed ID: 30527656
[TBL] [Abstract][Full Text] [Related]
11. Wound complications after chemo-port placement in children: Does closure technique matter?
Muncie C; Herman R; Collier A; Berch B; Blewett C; Sawaya D
J Pediatr Surg; 2018 Mar; 53(3):572-575. PubMed ID: 29113679
[TBL] [Abstract][Full Text] [Related]
12. The effect of bevacizumab on colon anastomotic healing in rats.
Pavlidis ET; Ballas KD; Symeonidis NG; Psarras K; Koliakos G; Kouzi-Koliakos K; Topouridou K; Rafailidis SF; Pavlidis TE; Marakis GN; Sakantamis AK
Int J Colorectal Dis; 2010 Dec; 25(12):1465-73. PubMed ID: 20689957
[TBL] [Abstract][Full Text] [Related]
13. [Complications associated with the placement of subcutaneous central venous access port devices: reasons for removal and complications observed].
Danno K; Ohnishi T; Watanabe A; Ueda M; Yanagawa T; Kim C; Fujita S; Fujita J; Yoshida T; Tono T; Monden T; Imaoka S
Gan To Kagaku Ryoho; 2012 Nov; 39(12):2404-6. PubMed ID: 23268092
[TBL] [Abstract][Full Text] [Related]
14. Safety of bevacizumab in metastatic breast cancer patients undergoing surgery.
Cortés J; Caralt M; Delaloge S; Cortes-Funes H; Pierga JY; Pritchard KI; Bollag DT; Miles DW
Eur J Cancer; 2012 Mar; 48(4):475-81. PubMed ID: 22196033
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant treatment of colorectal cancer with bevacizumab: the perioperative angiogenic balance is sensitive to systemic thrombospondin-1 levels.
Brostjan C; Gebhardt K; Gruenberger B; Steinrueck V; Zommer H; Freudenthaler H; Roka S; Gruenberger T
Clin Cancer Res; 2008 Apr; 14(7):2065-74. PubMed ID: 18381946
[TBL] [Abstract][Full Text] [Related]
16. Implantable subcutaneous infusion ports.
Soh LT; Ang PT
Support Care Cancer; 1993 Mar; 1(2):108-10. PubMed ID: 8143103
[TBL] [Abstract][Full Text] [Related]
17. [Surgical management of bevacizumab-associated peritonitis due to perforation].
Kube R; Meyer F; Bien N; Schmidt C; Mroczkowski P; Dalicho S; Lippert H
Zentralbl Chir; 2009 Sep; 134(5):462-7. PubMed ID: 19757347
[TBL] [Abstract][Full Text] [Related]
18. Angiogenesis inhibition with bevacizumab and the surgical management of colorectal cancer.
Thornton AD; Ravn P; Winslet M; Chester K
Br J Surg; 2006 Dec; 93(12):1456-63. PubMed ID: 17115389
[TBL] [Abstract][Full Text] [Related]
19. Central venous port system-related complications in outpatient chemotherapy for colorectal cancer.
Tsutsumi S; Fukasawa T; Fujii T; Tabe Y; Kigure W; Asao T; Kuwano H
Hepatogastroenterology; 2012 Jun; 59(116):1079-80. PubMed ID: 22580658
[TBL] [Abstract][Full Text] [Related]
20. Comparison of barbed versus conventional sutures for wound closure of radiologically implanted chest ports.
Ahmed O; Jilani D; Funaki B; Ginsburg M; Sheth S; Giger M; Zangan S
J Vasc Interv Radiol; 2014 Sep; 25(9):1433-8. PubMed ID: 24912877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
